Company intelligence / Profile preview

Fitterfly

Navi Mumbai, Maharashtra, Indiafitterfly.com ↗

Ownership: Private
Employees: ~150
Development stage: Commercial

Overview

Fitterfly’s digital therapeutics programs have demonstrated significant improvements in blood sugar control and weight loss among people with type 2 diabetes. Real-world trials show average HbA1c reduction of ~1.96%, average weight loss of 5 kg per participant over program duration, and notable improvements in physical fitness and reduction in diabetes distress. Their CGM-based program has been validated as a valuable adjunct for healthcare professionals managing type 2 diabetes.

Therapeutic areas: EndocrinologyCardiovascular
Modalities: Non-pharmacological therapyDeviceSmall molecule
Industry: Digital Health Medical Devices

Partnerships

Google Cloud (AI-powered food recognition via Gemini Flash)partnerships with insurance companies and pharmaceutical industry for SaaS/API integration of their platforms

Beyond the preview

Go deeper on Fitterfly.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fitterfly.

Explore the full profile